EC allows the sale of Glybera gene therapy

In a statement released on November 5, Dutch biotech company uniQure said it would start selling the first human gene therapy called Glybera in the European market next year.

The company predicts this will be the start of a boom for similar gene therapy businesses in the future.

On October 25, the European Commission (EC) agreed to allow the sale of Glybera gene therapy in the European and North American markets as a remedy to treat the rare human Lipoprotein Lipase disorder (LPLD). . Glybera will help prevent the metabolism of fat molecules fixed into the blood sugar.

Glybera gene therapy has been approved for sale in European and North American markets.

Gene therapy is generally used to modify a patient's DNA in a way that protects against specific diseases, which have been tested in treating many diseases ranging from blindness to depression and dementia symptoms. .

Glybera therapy helps treat LPLD, which is an extremely rare genetic disease because it only occurs in about 1-2 people / 1 million people.

Gene therapy appeared on medical regimens from the late 1990s of the last century and became one of the most attractive areas of biotechnology, promising to help prevent or repel Genetic diseases in the future.

In 2003, Chinese authorities also approved gene therapy to treat head and neck cancer.

However, scientists warn that this treatment often faces risks of unwanted or uncontrollable reactions from the immune system.

According to the report, gene therapy once caused the tragic death of 18-year-old volunteer, Jesse Gelsinger in 1999, and promoted the development of cancer tumors in two French children.